ARTICLE | Company News
Algen Biopharmaceuticals, BioLineRx deal
May 23, 2011 7:00 AM UTC
BioLineRx acquired exclusive rights to cancer candidate BL-7030 from Algen. The double-stranded RNA vector targeting EGFR is in preclinical testing. Algen has rights from the Hebrew University of Je...